Skip to main content
$17.27 -$0.20 (-1.1%)

02:45 PM EST on 02/28/24

Iovance Biotherapeutics Inc (NASDAQ:IOVA)

CAPS Rating: 2 out of 5

Current Price $17.27 Mkt Cap $4.9B
Open $17.26 P/E Ratio -8.40
Prev. Close $17.47 Div. (Yield) $0.00 (0.0%)
Daily Range $16.95 - $18.33 Volume 7,987,142
52-Wk Range $3.21 - $18.33 Avg. Daily Vol. 10,095,471


How do you think NASDAQ:IOVA will perform against the market?

Add Stock to CAPS Watchlist

All Players

31 Outperform
23 Underperform

All-Star Players

5 Outperform
9 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:IOVA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

zzlangerhans (98.75)
Submitted June 08, 2016

#zzporte has owned Lion since 2014 but I never could get excited enough about the position to enter a green thumb. The stock has gyrated quite a bit since we took our initial position but we never took advantage of the cycles and I recently… More


Fools bullish on NASDAQ:IOVA are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about IOVA.


Member Avatar techjunkie89 (36.55) Submitted: 5/3/2020 11:27:15 PM : Outperform Start Price: $31.68 NASDAQ:IOVA Score: -125.35

Leading cell therapy player with efficacy shown in solid tumors, strong buyout potential


Member Avatar zzlangerhans (98.75) Submitted: 6/8/2016 9:27:33 AM : Underperform Start Price: $8.20 NASDAQ:IOVA Score: +26.71

#zzporte has owned Lion since 2014 but I never could get excited enough about the position to enter a green thumb. The stock has gyrated quite a bit since we took our initial position but we never took advantage of the cycles and I recently liquidated the last of our position. The impetus to get out of Lion was a very weird day of trading last Friday in which the stock jumped from 6 to the mid 8's after announcement of a large below market dilutive financing at 4.75. I've never seen a stock rise after a below market financing before, and I never would have imagined it could happen by 50%. Usually a below market financing results in the stock closing even lower than the financing price because the discount is perceived as a sign of weakness. In this case the effective market cap rose from 292M (6 x 49M shares) to 593M (8.6 x 69M shares) during the trading day. That's an additional 300M in cap for raising 100M in cash.

I didn't see much commentary pointing out this completely bizarre reaction in share price, athough there were a couple of articles pointing out the simultaneous announcement of a new CEO. I'm sure the new CEO is great, but she wasn't the CEO of anything a month ago and no one hired her to be their CEO then. Just saying. And no one executive is worth 200M of additional cap anyway. Meanwhile, Lion continues the excruciatingly slow progress of their TIL pipeline. I feel like I've been hearing about TILs since I was in high school, and if they were going to be anything they would have been something by now. Lion hasn't even completed enrollment in a midstage trial. Before long this stock is going to find its way back to the 4.75 level that the recent investors got to buy at.


Member Avatar jed71 (46.64) Submitted: 7/7/2014 12:07:47 PM : Underperform Start Price: $6.90 NASDAQ:IOVA Score: +3.78

Not a long pitch here, I've got to get back to work. Just a few copy and paste's from the recent 10-Q. I am a HUGE fan of 1 for 100 reverse stock splits so felt I had to share this information. Company has no revenues to inception (back to 2007) and has changed business plans (restarted an inactive company in 2011) :

"Lion Biotechnologies, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated under the laws of the state of Nevada on September 17, 2007. Until March 2010, we were an inactive company known as Freight Management Corp. On March 15, 2010, we changed our name to Genesis Biopharma, Inc., and in 2011 we commenced our current business. On September 26, 2013, we amended and restated our Articles of Incorporation to, among other things, change our name to Lion Biotechnologies, Inc., effect a 1-for-100 reverse stock split (pro-rata reduction of outstanding shares) of our common stock, increase (after the reverse stock split) the number of our authorized number of shares of common stock to 150,000,000 shares, and authorize the issuance of 50,000,000 shares of “blank check” preferred stock, $0.001 par value per share."

"We have not had any revenues and are still in the development stage. As shown in the accompanying condensed financial statements, we have incurred a net loss of $2,259,514 for the three months ended March 31, 2014 and used $2,267,363 of cash in our operating activities during the three months ended March 31, 2014. On November 5, 2013, in a private placement (the “Private Placement”), we issued and sold 3,145,300 shares of common stock, 17,000 shares of Series A Convertible Preferred Stock, and warrants to purchase 11,645,300 shares of common stock for an aggregate purchase price of $23,290,600. The net proceeds of the Private Placement were approximately $21,985,000. As a result of the foregoing financing, as of March 31, 2014, we had $17,943,877 of cash or cash equivalents on hand, stockholders’ equity of $16,806,053 and had working capital of $16,958,482."

"Despite the amount of funds that we raised in the Private Placement, the estimated cost of completing the development of our TIL therapy, and of obtaining all required regulatory approvals to market those product candidates, is substantially greater than the amount of funds we currently have available. While we believe that our existing cash balances will be sufficient to fund our currently planned level of operations for at least twelve months, we will have to obtain additional funds through various financing sources, including possible sales of our securities and strategic alliances with other pharmaceutical or biopharmaceutical companies, in order to fund all of our anticipated product development costs."


Find the members with the highest scoring picks in IOVA.

Score Leader


SueInVirginia (80.20) Score: +465.74

The Score Leader is the player with the highest score across all their picks in IOVA.

Member Name Member
Call Time
Score Commentary
DorminABC 99.54 7/25/2011 Underperform NS $154.00 -88.68% +279.91% +368.59 0 Comment
mrmrmrj 48.81 10/17/2023 Outperform 5Y $3.71 +370.08% +17.01% +353.07 0 Comment
tortuga94 61.41 9/29/2023 Outperform 5Y $4.55 +283.30% +17.96% +265.34 0 Comment
allforone 72.52 9/18/2023 Outperform 1Y $6.06 +188.03% +13.96% +174.06 0 Comment
conliskjr < 20 8/31/2023 Outperform 3Y $6.16 +183.12% +12.66% +170.46 0 Comment
Zencyclone 38.00 3/17/2015 Underperform 5Y $13.32 +30.93% +143.83% +112.90 0 Comment
monkeyjaws 49.89 3/12/2015 Underperform 5Y $12.39 +40.76% +144.64% +103.88 0 Comment
OttoLutz 50.36 7/19/2019 Underperform 5Y $26.12 -33.23% +69.26% +102.49 0 Comment
kkconway 84.17 6/20/2023 Outperform 1Y $8.04 +116.92% +16.21% +100.71 0 Comment
Mangot1me 39.44 3/24/2015 Underperform 5Y $12.23 +42.60% +141.32% +98.72 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for IOVA.